Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- Netherlands
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to transplant Response to transplant,response to transplant
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Allogenic (Baseline samples)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Allogenic (6 weeks samples)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Fecal samples collected from the participants 6 weeks after allogenic lean donor gut microbiota treatment.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 9
- Group 1 sample size Number of subjects in the case (exposed) group
- 9
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Human Intestinal Tract Chip
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mixed-Effects Regression
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Source: Supplementary Table 3
Description: Significant changes in 16 fecal gut microbiota within the allogenic lean donor gut microbiota treatment group after 6 weeks
Abundance in Group 1: increased abundance in Allogenic (6 weeks samples)
Revision editor(s): Aleru Divine, WikiWorks
Experiment 3
Curated date: 2025/02/04
Curator:
Revision editor(s):
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Autologous (6 weeks samples)
Lab analysis
Statistical Analysis
Signature 1
Source: Supplementary Table 3
Description: Differences in gut microbiota identified between allogenic and autologous treatment groups.
Abundance in Group 1: increased abundance in
NCBI | Quality Control | Links |
---|---|---|
Dorea formicigenerans | ||
Lacrimispora sphenoides | ||
Coprobacillus cateniformis | ||
[Ruminococcus] lactaris | ||
[Clostridium] nexile | ||
Oxalobacter formigenes |
Revision editor(s): Aleru Divine, WikiWorks
Experiment 4
Subjects
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Small intestine Anterior intestine,Intestinum tenue,Mid intestine,Small bowel,Small intestine,small intestine
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Small intestinal biopsy samples collected from the participants 6 weeks after allogenic lean donor gut microbiota treatment.
Lab analysis
Statistical Analysis
Signature 1
Source: Supplementary Table 4
Description: Differences in gut microbiota identified between allogenic and autologous treatment groups.
Abundance in Group 1: increased abundance in Allogenic (6 weeks samples)
NCBI | Quality Control | Links |
---|---|---|
Escherichia coli | ||
Corynebacterium sp. | ||
Alcaligenes faecalis |
Revision editor(s): Aleru Divine, WikiWorks